



## 8<sup>TH</sup> IAS CONFERENCE ON PATHOGENESIS, TREATMENT AND PREVENTION (IAS 2015)

### COMPLETE PRESS CONFERENCE SCHEDULE

Please note that official IAS 2015 press conferences will be livestreamed. [You may access the briefings live here.](#)

TIME (PDT)	THEME/TOPIC	SPEAKERS
SUNDAY 19 July 17.30-18.30	<p><b>Official IAS 2015 Opening Press Conference</b></p> <ul style="list-style-type: none"> <li>• Overview of newsworthy data and other announcements at the conference</li> <li>• Preview of select plenary addresses</li> <li>• Discussion of global HIV treatment targets</li> <li>• 30/30 Project, founded by musician and director Ryan Lewis (known for his collaborations with Macklemore) and his mother, Julie Lewis (a 30-year HIV survivor)</li> </ul>	<p><b>Press Conference Chair:</b></p> <ul style="list-style-type: none"> <li>• Chris Beyrer, MD, Johns Hopkins University, IAS 2015 International Chair &amp; International AIDS Society President</li> </ul> <p><b>Speakers:</b></p> <ul style="list-style-type: none"> <li>• Chris Beyrer, MD</li> <li>• Julio Montaner, MD, IAS 2015 Local Co-Chair; Director, British Columbia Centre for Excellence in HIV/AIDS</li> <li>• Nora Volkow, MD, Director, U.S. National Institute on Drug Abuse</li> <li>• Michel Sidibé, Executive Director, UNAIDS</li> <li>• Amb. Deborah Birx, MD, U.S. Global AIDS Coordinator</li> <li>• Ryan &amp; Julie Lewis, Founders, 30/30 Project</li> </ul>
MONDAY 20 July 9.15-10.15	<p><b>Official IAS 2015 Press Conference: Earlier Initiation of HIV Treatment, Treatment as Prevention (TasP) &amp; Non-Daily PrEP Use</b></p> <ul style="list-style-type: none"> <li>• Full results from the Strategic Timing of Antiretroviral Treatment (START) study, a trial recently stopped early based on preliminary data that clearly showed individuals with HIV have a</li> </ul>	<p><b>Press Conference Chair:</b></p> <ul style="list-style-type: none"> <li>• Julio Montaner, MD, IAS 2015 Local Co-Chair; Director, British Columbia Centre for Excellence in HIV/AIDS</li> </ul> <p><b>Speakers:</b></p> <ul style="list-style-type: none"> <li>• Jens Lundgren, MD (START), University of</li> </ul>

	<p>considerably lower risk of developing AIDS or other serious illnesses if they begin ARV treatment soon after diagnosis (Session#: MOSY03)</p> <ul style="list-style-type: none"> <li>• Final data from HPTN 052 – a landmark trial – answering whether dramatic decreases in sexual transmission of HIV from individuals whose infections were suppressed through therapy were sustained over the course of the multi-year study (Session#: MOAC01)</li> <li>• Preview of updated WHO ARV guidelines, including guidance on pre-exposure prophylaxis (PrEP)</li> <li>• Findings from the HPTN 067 ADAPT trial examining adherence and other factors related to the use of non-daily (or intermittent) PrEP in Cape Town, Bangkok and Harlem; findings will have significant implications for PrEP rollout worldwide and for the use among women and men who have sex with men (MSM) (Session#: MOSY01)</li> </ul>	<p>Copenhagen</p> <ul style="list-style-type: none"> <li>• Myron Cohen, MD (HPTN 052), University of North Carolina School of Medicine</li> <li>• Gottfried Hirnschall, MD (ARV Guidelines), WHO</li> <li>• Bob Grant, MD (ADAPT), University of California, San Francisco</li> <li>• Dazon Dixon Diallo (Community Perspective), SisterLove, Inc., Atlanta</li> </ul>
<p>MONDAY 20 July 12.30-13.15</p>	<p><b>Médecins Sans Frontières (MSF) / Doctors without Borders*</b></p> <p>10 years of MSF data exposes major fault lines for reaching 90% undetectable among people on ART</p> <p><i>* Not an official IAS press conference</i></p>	<p><b>Speakers:</b></p> <ul style="list-style-type: none"> <li>• Sharonann Lynch, HIV/AIDS Policy Adviser, MSF</li> <li>• Dr. Helen Bygrave, South African Medical Unit, MSF</li> </ul>
<p>MONDAY 20 July 16.30-17.30</p>	<p><b>Official IAS 2015 Press Conference: PrEP Implementation</b></p> <ul style="list-style-type: none"> <li>• First data from the US PrEP Demo Project exploring PrEP adherence, sexual behaviors and HIV/STI incidence among MSM and transgender women in Miami, San Francisco and Washington, DC</li> <li>• Results from PrEP Brasil, the first PrEP demonstration project for MSM and transgender women in a middle-income country</li> <li>• Data from ATN 110 examining PrEP uptake and adherence among young MSM in 12 U.S. cities</li> <li>• Final results from TDF2 OLE PrEP study, the U.S. Centers for Disease Control &amp; Prevention's 12-month open-label extension</li> </ul>	<p><b>Press Conference Chair:</b></p> <ul style="list-style-type: none"> <li>• Chris Beyrer, MD, IAS 2015 International Chair; President, International AIDS Society; Professor, The Johns Hopkins University</li> </ul> <p><b>Speakers:</b></p> <ul style="list-style-type: none"> <li>• Albert Liu, MD (U.S. PrEP Demo), San Francisco Department of Public Health</li> <li>• Beatriz Grinsztejn, MD (PrEP Brasil), Instituto Pesq Clinica Evandro Chagas, Rio de Janeiro</li> </ul>

	<p>trial assessing PrEP use among young heterosexual adults in Botswana</p> <p>(Note: All above presentations will be featured in Session #: TUAC02)</p> <ul style="list-style-type: none"> <li>• Overview of a special PrEP-themed issue of the <i>Journal of the International AIDS Society</i> (JIAS)</li> </ul>	<ul style="list-style-type: none"> <li>• Sybil Hosek, PhD (ATN 110), Stroger Hospital, Chicago</li> <li>• Faith Henderson (TDF2 OLE), CDC</li> <li>• Carlos F. Cáceres, MD (JIAS), Cayetano Heredia University, Lima</li> </ul>
<p>TUESDAY 21 July 9.15-10.15</p>	<p><b>Official IAS 2015 Press Conference: Towards an HIV Cure</b></p> <p>The press briefing will reflect on where the field of HIV cure research has come in the past year and where it may be headed, and focus on key studies being presented in Vancouver, including:</p> <ul style="list-style-type: none"> <li>• Case of a perinatally HIV-infected adolescent showing unprecedented virological remission many years after ARV discontinuation (Abstract#: MOAA0105LB)</li> <li>• Convergence of research suggesting that broadly neutralizing antibodies may play a key role in developing both a vaccine and a cure for HIV</li> <li>• First-time findings on Zinc Finger Nuclease genome editing – describing use of long-term, multi-lineage engraftment of gene-edited immune cells targeting the CCR5 protein necessary for HIV cell infection (Abstract #: TUAA0202)</li> </ul>	<p><b>Press Conference Co-Chairs:</b></p> <ul style="list-style-type: none"> <li>• Françoise Barré-Sinoussi, PhD, Institut Pasteur, Paris</li> <li>• Sharon Lewin, PhD, University of Melbourne</li> <li>• Steven Deeks, MD, University of California, San Francisco</li> </ul> <p><b>Speakers:</b></p> <ul style="list-style-type: none"> <li>• Asier Saez-Cirion, PhD (Long-Term Remission), Institut Pasteur, Paris</li> <li>• John Mascola, MD (Broadly Neutralizing Antibodies), U.S. National Institutes of Health</li> <li>• Sarah Fidler, MD (Partnerships), Imperial College London</li> <li>• Christopher Peterson, PhD (Zinc Finger), Fred Hutchinson Cancer Research Centre, Seattle</li> <li>• Lynda Dee (Community Perspective), AIDS Action Baltimore</li> </ul>
<p>TUESDAY 21 July 11.00-11.45</p>	<p><b>WHO Testing Guidelines Update*</b></p> <p><i>* Not an official IAS press conference</i></p>	<p><b>Speaker:</b></p> <ul style="list-style-type: none"> <li>• Gottfried Hirschall, MD, WHO</li> </ul>
<p>TUESDAY 21 July</p>	<p><b>Médecins Sans Frontières (MSF) / Doctors without Borders*</b></p>	<p><b>Speaker:</b></p> <ul style="list-style-type: none"> <li>• Leena Menghaney, India Coordinator of</li> </ul>

12:30-13.15	Access to the affordable HIV treatment under threat: the dangers of the TPP and trade agreements with India  <i>* Not an official IAS press conference</i>	MSF's Access Campaign (TBC)
TUESDAY 21 July 15.30-16.15	<b>IFARA*</b>  Introduction to Young Investigators Awardees.  <i>*Not an official IAS press conference</i>	<b>Speaker:</b> • Fred Schaich, President, IFARA
WEDNESDAY 22 July 9.15-10.15	<b>Official IAS 2015 Press Conference: HIV-Hepatitis Co-Infection</b>  The press briefing will provide an overview of key treatment and other research presented at the conference, latest prevention approaches and expansion of global access to treatment/prevention of hepatitis B and C among people co-infected with HIV.	<b>Press Conference Chair:</b> • Linda-Gail Bekker, Desmond Tutu HIV Centre, Cape Town  <b>Speakers:</b> • Tracy Swan, Treatment Action Group • Anchalee Avihingsanon, MD, Thai Red Cross - AIDS Research Centre • Marina Klein, MD, McGill University, Canada • Jürgen Rockstroh, MD, University of Bonn, Germany
WEDNESDAY 22 July 11.00 -11.45	<b>Society for AIDS in Africa*</b>  International Conference on AIDS and STI's In Africa (ICASA) update and announcement.  <i>* Not an official IAS press conference</i>	<b>Speaker:</b> • Dr. Ihab Ahmed Abdelrahman Ahmed, President for Soceity for AIDS in Africa(SAA) & ICASA 2015 President. • Ambassador Florence Zano Chideya, Dean of the Diplomatic Corps in Canada • Prof. John Idoko, Soceity for AIDS in Africa Board Member • Dr. Tapuwa Magure, CEO, National AIDS Council of Zimbabwe • Prof Serge Paul Eholie

<p>WEDNESDAY 22 July 13.00 -13.45</p>	<p><b>British Columbia Centre for Excellence in HIV/AIDS*</b></p> <p>Signing of a letter of intent between the British Columbia Centre for Excellence in HIV/AIDS and the government of Brazil.</p> <p><i>* Not an official IAS press conference</i></p>	<p><b>Speaker:</b></p> <ul style="list-style-type: none"><li>• Julio Montaner, MD, Director, British Columbia Centre for Excellence in HIV/AIDS</li><li>• Fabio Mesquita, MD, Director, Department of STDs, AIDS and Viral Hepatitis, Ministry of Health, Brazil</li></ul>
---	--	--